

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number  
**WO 2005/065771 A1**

(51) International Patent Classification<sup>7</sup>: A61N 1/36, 1/05

(21) International Application Number:  
PCT/US2004/043691

(22) International Filing Date:  
23 December 2004 (23.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/746,852 24 December 2003 (24.12.2003) US  
10/746,861 24 December 2003 (24.12.2003) US

(71) Applicant (for all designated States except US): CAR-  
DIAC PACEMAKERS, INC. [US/US]; 4100 Hamline  
Avenue North, St. Paul, MN 55112 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LIBBUS, Imad  
[US/US]; 1726 Stanford Avenue, St. Paul, MN 55105  
(US). HEIL, Ronald, W., Jr. [US/US]; 2312 Western  
Avenue North, Roseville, MN 55113 (US). SCHEINER,  
Avram [US/US]; 4403 Meadowood Circle, Vadnais  
Heights, MN 55127 (US). KELLEY, Peter, T. [US/US];  
1347 Dague Avenue SE, Buffalo, MN 55313 (US).

(74) Agents: STEFFEY, Charles, E. et al.; Schwegman, Lund-  
berg, Woessner & Kluth, P.A., P.O. Box 2938, Minneapolis,  
MN 55402 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: LEAD FOR STIMULATING THE BARORECEPTORS IN THE PULMONARY ARTERY



(57) Abstract: An apparatus includes a flexible lead body, an electrode coupled to the lead body, and an implantable pulse generator electrically coupled to the electrode. The implantable pulse generator is adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode. The apparatus includes means for passively fixating the electrode within the pulmonary artery.

## LEAD FOR STIMULATING THE BARORECEPTORS IN THE PULMONARY ARTERY

5

### Cross Reference To Related Applications

The following commonly assigned U.S. patent applications are related, are all filed on the same date as the present application and are all herein incorporated by reference in their entirety: "Baroreflex Stimulation System to Reduce Hypertension," Ser. No. <sup>10/746,134</sup>\_\_\_\_\_, (Attorney Docket No. 279.675US1); and  
10 "Stimulation Lead for Stimulating the Baroreceptors in the Pulmonary Artery," Ser. No. <sup>10/746,134</sup>\_\_\_\_\_, (Attorney Docket No. 279.695US1).  
052

### Field

This application relates generally to implantable medical devices and, more  
15 particularly, to systems, devices and methods for reducing hypertension using baroreceptor stimulation.

### Background

Medical leads have a distal end having one or more electrodes and a  
20 proximal end having a terminal that is coupled to a pulse generator. Electrical therapy is delivered from the pulse generator to the body via the electrode.

Hypertension is a cause of heart disease and other related cardiac co-morbidities. Hypertension occurs when blood vessels constrict. As a result, the heart works harder to maintain flow at a higher blood pressure, which can contribute  
25 to heart failure. Many patients who suffer from hypertension do not respond to treatment, such as treatments related to lifestyle changes and hypertension drugs.

A pressoreceptive region is capable of sensing changes in pressure, such as changes in blood pressure. Pressoreceptor regions are referred to herein as

baroreceptors, which generally include any sensors of pressure changes. For example, baroreceptors include afferent nerves and further include sensory nerve endings that are sensitive to the stretching of the wall that results from increased blood pressure from within, and function as the receptor of a central reflex  
5 mechanism that tends to reduce the pressure. Baroreflex functions as a negative feedback system, and relates to a reflex mechanism triggered by stimulation of a baroreceptor. Increased pressure stretches blood vessels, which in turn activate baroreceptors in the vessel walls. Activation of baroreceptors naturally occurs through internal pressure and stretching of the arterial wall, causing baroreflex  
10 inhibition of sympathetic nerve activity (SNA) and a reduction in systemic arterial pressure. An increase in baroreceptor activity induces a reduction of SNA, which reduces blood pressure by decreasing peripheral vascular resistance.

The general concept of stimulating afferent nerve trunks leading from baroreceptors is known. For example, direct electrical stimulation has been applied  
15 to the vagal nerve and carotid sinus using nerve cuffs. Research has indicated that electrical stimulation of the carotid sinus nerve can result in reduction of experimental hypertension, and that direct electrical stimulation to the pressoreceptive regions of the carotid sinus itself brings about reflex reduction in experimental hypertension.

20 What is needed is a less invasive technique for providing long-term electrical stimulation of the baroreflex.

### Summary

One aspect includes a flexible lead body extending from a proximal end to a  
25 distal end and having an expandable electrode coupled proximate the distal end of the lead body. The expandable electrode has an expanded diameter dimensioned to abut a wall of a pulmonary artery. An implantable pulse generator is electrically coupled to the expandable electrode and is adapted to deliver a baroreflex

stimulation signal to a baroreceptor in the pulmonary artery via the expandable electrode.

One aspect includes a method. The method includes implanting an expandable electrode within a pulmonary artery such that an outer surface of the expandable electrode abuts a wall of the pulmonary artery, and delivering a  
5 baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.

One aspect provides a lead for placement in the pulmonary artery. The lead includes a flexible lead body extending from a proximal end to a distal end, the  
10 distal end having a biased portion having an outer diameter dimensioned to abut a wall of a pulmonary artery, an electrode coupled proximate the distal end. An implantable pulse generator is electrically coupled to the electrode. The implantable pulse generator is adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.

One aspect includes a method. The method includes positioning an electrode  
15 on a distal end of a lead within a pulmonary artery, the distal end having a biased portion such that an outer diameter of the biased portion abuts a wall of the pulmonary artery, and delivering a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.

20

### **Brief Description of the Drawings**

Figure 1 shows a lead and pulse generator, in accordance with one embodiment.

25 Figure 2 shows details of a heart.

Figure 3 shows the lead of Figure 1 implanted in a heart, in accordance with one embodiment.

Figure 4 shows a lead having an expandable electrode in accordance with one embodiment.

Figure 5 shows the lead of Figure 4 with the electrode in an expanded configuration.

5        Figure 6 shows an expandable electrode in accordance with one embodiment.

Figure 7 shows a side view of a lead in accordance with one embodiment.

Figure 8 shows a lead and pulse generator, in accordance with one embodiment.

10       Figure 9 shows the lead of Figure 8 implanted in a heart, in accordance with one embodiment.

Figure 10 shows a lead in accordance with one embodiment.

Figure 11 shows the lead of Figure 10 with the distal end in a biased configuration.

15       Figure 12 shows a lead in accordance with one embodiment.

Figure 13 shows a side view of a lead in accordance with one embodiment.

Figure 14 shows a portion of a lead in accordance with one embodiment.

Figure 15 shows a lead implanted in accordance with one embodiment.

20

### **Detailed Description**

The following detailed description and accompanying drawings show specific embodiments in which the present invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to  
25       practice the invention. Other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.

A brief discussion of hypertension and the physiology related to baroreceptors is provided to assist the reader with understanding this disclosure.

This brief discussion introduces hypertension, the autonomic nervous system, and baroreflex.

Hypertension is a cause of heart disease and other related cardiac co-morbidities. Hypertension generally relates to high blood pressure, such as a  
5 transitory or sustained elevation of systemic arterial blood pressure to a level that is likely to induce cardiovascular damage or other adverse consequences.

Hypertension has been arbitrarily defined as a systolic blood pressure above 140 mm Hg or a diastolic blood pressure above 90 mm Hg. Hypertension occurs when blood vessels constrict. As a result, the heart works harder to maintain flow at a higher  
10 blood pressure. Consequences of uncontrolled hypertension include, but are not limited to, retinal vascular disease and stroke, left ventricular hypertrophy and failure, myocardial infarction, dissecting aneurysm, and renovascular disease.

The autonomic nervous system (ANS) regulates “involuntary” organs, while the contraction of voluntary (skeletal) muscles is controlled by somatic motor  
15 nerves. Examples of involuntary organs include respiratory and digestive organs, and also include blood vessels and the heart. Often, the ANS functions in an involuntary, reflexive manner to regulate glands, to regulate muscles in the skin, eye, stomach, intestines and bladder, and to regulate cardiac muscle and the muscle around blood vessels, for example.

20 The ANS includes, but is not limited to, the sympathetic nervous system and the parasympathetic nervous system. The sympathetic nervous system is affiliated with stress and the “fight or flight response” to emergencies. Among other effects, the “fight or flight response” increases blood pressure and heart rate to increase skeletal muscle blood flow, and decreases digestion to provide the energy for  
25 “fighting or fleeing.” The parasympathetic nervous system is affiliated with relaxation and the “rest and digest response” which, among other effects, decreases blood pressure and heart rate, and increases digestion to conserve energy. The ANS maintains normal internal function and works with the somatic nervous system.

The subject matter of this disclosure generally refers to the effects that the ANS has on the heart rate and blood pressure, including vasodilation and vasoconstriction. The heart rate and force is increased when the sympathetic nervous system is stimulated, and is decreased when the sympathetic nervous system is inhibited (e.g. when the parasympathetic nervous system is stimulated).

Baroreflex is a reflex triggered by stimulation of a baroreceptor. A baroreceptor includes any sensor of pressure changes, such as sensory nerve endings in the wall of the auricles of the heart, cardiac fat pads, vena cava, aortic arch and carotid sinus, that is sensitive to stretching of the wall resulting from increased pressure from within, and that functions as the receptor of the central reflex mechanism that tends to reduce that pressure. Additionally, a baroreceptor includes afferent nerve trunks, such as the vagus, aortic and carotid nerves, leading from the sensory nerve endings. Stimulating baroreceptors inhibits sympathetic nerve activity (stimulates the parasympathetic nervous system) and reduces systemic arterial pressure by decreasing peripheral vascular resistance. Baroreceptors are naturally stimulated by internal pressure and the stretching of the arterial wall.

Some aspects of the present subject matter locally and directly stimulate specific nerve endings in arterial walls rather than stimulate afferent nerve trunks in an effort to stimulate a desired response (e.g. reduced hypertension) while reducing the undesired effects of indiscriminate stimulation of the nervous system. For example, some embodiments stimulate baroreceptor sites in the pulmonary artery. Some embodiments of the present subject matter involve stimulating baroreceptor sites in the aorta.

Figure 1 shows a lead 100 according to one embodiment. Lead 100 includes a flexible lead body 110 extending from a proximal end 115 to a distal end 120. An expandable electrode 130 is coupled proximate the distal end 120 of lead body 110. As will be discussed below, electrode 130 is adapted to deliver stimulation to baroreceptors in the pulmonary artery. For example, the expandable electrode 130

can have an expanded diameter dimensioned to abut a wall of a pulmonary artery to hold the electrode in place without any active fixation.

Lead 100 is coupled to an implantable pulse generator 140. Lead 100 includes conductors, such as coiled conductors that electrically couple pulse generator 140 to expandable electrode 130. Accordingly, implantable pulse generator 140 can deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode 130. The lead further includes outer insulation to insulate the conductor. The system can include a unipolar system with the case acting as an electrode or a bipolar system with a pulse between two distally located electrodes.

In one embodiment, pulse generator 140 includes hardware, circuitry and software to perform NS functions. Some embodiments can also perform an AHT function. Pulse generator includes controller circuitry 142. The controller circuitry 142 is capable of being implemented using hardware, software, and combinations of hardware and software. For example, according to various embodiments, the controller circuitry 142 includes a processor to perform instructions embedded in a memory to perform functions associated with NS therapy such as AHT therapy. In one example, the pulse generator delivers a pulse train having a frequency of between 10 to 150 hertz via the electrode.

Figure 2 shows a representation of a portion of a heart 200. Heart 200 includes an aortic arch 203 and a pulmonary artery 204. Pulmonary artery 204 includes a plurality of baroreceptors 206. A lead, such as lead 100 (Fig. 1), is capable of being intravascularly inserted through a peripheral vein and through the tricuspid valve into the right ventricle of the heart (not expressly shown in the figure) similar to a cardiac pacemaker lead, and continue from the right ventricle through the pulmonary valve 208 into the pulmonary artery 204.

A portion of the pulmonary artery 204 and aorta arch 203 are proximate to each other. According to various aspects of the present subject matter, the



baroreflex is stimulated in or around the pulmonary artery by at least one electrode intravascularly inserted into the pulmonary artery. Aspects of the present subject matter provide a relatively noninvasive surgical technique to implant a baroreceptor stimulator intravascularly into the pulmonary artery. The baroreceptors 206, for  
5 example, are sensitive to stretching of the wall resulting from increased pressure from within. Activation of these nerve endings reduce pressure.

As illustrated, the pulmonary artery 204 includes a number of baroreceptors 206, as generally indicated by the dark areas. Furthermore, a cluster of closely spaced baroreceptors 206B are situated near the attachment of the ligamentum  
10 arteriosum 212. According to various embodiments of the present subject matter, a lead is inserted through a peripheral vein and threaded through the tricuspid valve into the right ventricle, and from the right ventricle through the pulmonary valve 208 and into the pulmonary artery 204 to simulate baroreceptors in and/or around the pulmonary artery. In various embodiments, for example, the lead is positioned in  
15 the artery to stimulate the cluster of baroreceptors 206B near the ligamentum arteriosum 212.

There are also baroreceptor fields in the aortic arch 203, near the ligamentum arteriosum 212, and in the trunk 220 of the pulmonary artery 204. Some  
20 embodiments position the lead in the pulmonary artery to stimulate baroreceptor sites in the aorta, possibly via the ligamentum arteriosum 212, or in the pulmonary trunk, or in either the right or left pulmonary arteries.

Figure 3 shows expandable electrode 130 mounted in pulmonary artery 204, in accordance with one embodiment. In one embodiment, expandable electrode 130 is a stent-like structure including a mesh surface 302. The expandable electrode is  
25 designed to expand to abut the outer walls 304 of the pulmonary artery so as to passively fixate the lead and the electrode in place by frictional forces. In this example, the electrode is adapted to be located near the ligamentum arteriosum 212 of the left pulmonary artery 204.

Expandable electrode 130 can have various shapes and sizes. In one embodiment, the length to diameter ratio is smaller than in typical stents. For example, one embodiment includes a length of at least about 1 cm. Other examples can be up to 3 cm or greater. The diameter of the electrode 130 in its expanded orientation can range from about 10 mm to about 20 mm. Other embodiments can have a larger diameter. In general, the electrode is dimensioned to provide direct, low-voltage, high-frequency nerve stimulation.

In one embodiment, lead 100 can include a second electrode 312 located proximally from the expandable electrode 130. This electrode can be used for bradyarrhythmia therapy, tachyarrhythmia therapy, as a sensing electrode, or as a cathode for electrode 130.

In one example, electrode 130 is adapted to be chronically implanted in the pulmonary artery. For example, by passively mounting the electrode within the artery, no long-term damage is done to the artery.

Figures 4 and 5 show lead 100, in accordance with one embodiment. Lead 100 can include an inflatable balloon 402 that can be inflated once the electrode is positioned correctly. Inflating the balloon 402 expands the electrode 130 until the electrode abuts the walls of the artery, as discussed above.

Figure 6 shows an expandable electrode 630, in accordance with one embodiment. Electrode 630 can be used in place of electrode 130 discussed above. Electrode 630 includes an outer surface 640 that can be at least partially masked so as to be electrically non-conductive. For example, electrode 630 has been marked off into zones A, B, and C. Zones A, B, and C can have varying sizes and shapes and the zones shown are an example. In one example, sections A and C can be electrically conductive and zone B is masked off. Alternatively, any of the sections or portions can be electrically insulated.

In one embodiment, none of sections A, B, or C is masked off and each is coupled to a separate conductor of lead 100 (Figure 1). In this example, the user

implants the electrode and then tests each zone separately to discover which gives the best baroreflex response. Then, the non-productive zones can be turned off, or used for sensing, for example.

Figure 7 illustrates a baroreceptor stimulation lead 700 with an integrated  
5 pressure sensor 710 (IPS) and an expandable electrode 702, according to various  
embodiments of the present subject matter. In one example, lead 700 can include an  
IPS 710 with a baroreceptor stimulator electrode 712 to monitor changes in blood  
pressure, and thus to monitor the effect of the baroreceptor stimulation. In various  
embodiments, micro-electrical mechanical systems (MEMS) technology can be used  
10 to sense the blood pressure. Some sensor embodiments determine blood pressure  
based on a displacement of a membrane.

In one example use of lead 700, a system can include baroreceptor  
stimulation circuitry and sensor circuitry. The circuitry can be within pulse  
generator 140 (Figure 1) or be a separate system communicating wirelessly with the  
15 pulse generator. One or more leads can be connected to the sensor circuitry and  
baroreceptor stimulation circuitry. The baroreceptor stimulation circuitry is used to  
apply electrical stimulation pulses to desired baroreceptors sites, such as  
baroreceptor sites in the pulmonary artery, through one or more stimulation  
electrodes, such as electrodes 702 or 712. The sensor circuitry is used to detect and  
20 process ANS nerve activity and/or surrogate parameters such as blood pressure,  
respiration and the like, to determine the ANS activity.

Lead 700, for example, is capable of being intravascularly introduced to  
stimulate a baroreceptor site, such as the baroreceptor sites in the pulmonary artery,  
aortic arch, or ligamentum arteriosum. One or more additional electrodes can be  
25 provided to pace and/or sense cardiac activity, such as that which may occur within  
the right ventricle with the sensor 710 located near baroreceptors in or near the  
pulmonary artery and programmed to stimulate and sense, either directly or  
indirectly through surrogate parameters, baroreflex activity.

Figure 8 shows a lead 1100 according to one embodiment. Lead 1100 includes a flexible lead body 1110 extending from a proximal end 1115 to a distal end 1120. An electrode 1130 is coupled proximate the distal end 1120 of lead body 1110. The distal end 1120 includes a biased portion 1122. Lead 1100 is adapted to deliver stimulation to baroreceptors in the pulmonary artery. For example, the biased portion 1122 can have a biased configuration having an outer diameter, D, dimensioned to abut a wall of a pulmonary artery to hold the electrode in place without any active fixation, as will be explained below.

Lead 1100 is coupled to an implantable pulse generator 1140. Lead 1100 includes conductors, such as coiled conductors that electrically couple pulse generator 1140 to electrode 1130. Accordingly, implantable pulse generator 1140 can deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode 1130. The lead further includes outer insulation to insulate the conductor. The system can include a unipolar system with the case acting as an electrode or a bipolar system with a pulse between two distally located electrodes.

In one embodiment, pulse generator 1140 includes hardware, circuitry and software to perform NS functions. Some embodiments can also perform an AHT function. Pulse generator includes controller circuitry 1142. The controller circuitry 1142 is capable of being implemented using hardware, software, and combinations of hardware and software. For example, according to various embodiments, the controller circuitry 1142 includes a processor to perform instructions embedded in a memory to perform functions associated with NS therapy such as AHT therapy. In one example, the pulse generator delivers a pulse train having a frequency of between about 10 to 150 hertz via the electrode. In one embodiment, the pulse generator can deliver a waveform of 30 hertz, 2.5 msec, at 5 volts. Some embodiments deliver a waveform of 100 hertz, 1.0 msec, at 1, 3, or 5 volts, for example.

Figure 9 shows a cross-section of electrode 1130 mounted in pulmonary artery 204, in accordance with one embodiment. In one embodiment, biased portion 1122 includes an elongated spiral configuration with electrode 1130 being a coiled electrode that is exposed to have substantially complete annular contact with the wall surface 304 of the pulmonary artery 204. This allows for distributed stimulation along the length of the biased portion 1122 and distributed wall fixation. Thus, for example, the entire electrode 1130 can be an exposed electrode manufactured in a spiral configuration. As will be discussed below, some embodiments can include two or more discrete electrodes placed along the distal end of the lead. In some embodiments, portions of the surface of the electrode can be masked off to be electrically insulated.

As noted, the outer diameter of the biased portion 1122 is designed to expand to abut the outer walls 304 of the pulmonary artery so as to fix the lead and the electrode in place by frictional forces. In this example, the electrode is adapted to be located near the ligamentum arteriosum 212 of the left pulmonary artery 204. In some embodiments, at least a portion of electrode 1130 can include a porous surface to further help fix the electrode within the artery.

In one embodiment, the biased portion 1122 can have an outer biased diameter of about 10 mm to about 20 mm. Other embodiments can have a larger diameter. One example has a pitch of at least 5 coils per inch to provide high arterial surface contact and increased fixation. In general, the distal end and the electrode are dimensioned to optimize direct, low-voltage, high-frequency nerve stimulation.

In one embodiment, lead 1100 can include a second electrode 1312 located proximally from electrode 1130. This electrode can be used for bradyarrhythmia therapy, tachyarrhythmia therapy, as a sensing electrode, or as a cathode for electrode 1130.

In one example, electrode 1130 is adapted to be chronically implanted in the pulmonary artery. For example, by passively mounting the electrode within the artery, no long-term damage is done to the artery.

Figures 10 and 11 show lead 1100, in accordance with one embodiment.

- 5    Lead 1100 can be implanted using a stylet 1402 that is removed once the lead is positioned correctly. Removing stylet 1402 from the lead allows distal end 1122 to expand to its biased configuration until the electrode abuts the walls of the artery, as discussed above.

- 10    Figure 12 shows a portion of a lead 1600, in accordance with one embodiment. Lead 1600 includes a biased distal portion 1622, similar to biased portion 1122 discussed above. In this embodiment, the biased portion 1622 includes two or more discrete electrodes 1624 exposed on the outer surface and outer diameter of the biased portion. In one embodiment, these discrete electrodes allow localized, but distributed stimulation when implanted in an artery. Alternatively,
- 15    some of the discrete electrodes 1624 can be coupled to a separate conductor of lead 1600. In this example, the user implants the electrode and then tests each electrode separately to discover which gives the best baroreflex response. Then, the non-productive electrode or electrodes can be turned off, or used only for sensing, or other purposes. In some embodiments, discrete electrodes 1624 can be porous to
- 20    provide further fixation within the artery.

- Figure 13 illustrates a baroreceptor stimulation lead 1700 with an integrated pressure sensor 1710 (IPS), according to various embodiments of the present subject matter. Lead 1700 can include an IPS 1710 with a baroreceptor stimulator electrode to monitor changes in blood pressure, and thus to monitor the effect of the
- 25    baroreceptor stimulation. In various embodiments, micro-electrical mechanical systems (MEMS) technology can be used to sense the blood pressure. Some sensor embodiments determine blood pressure based on a displacement of a membrane.

In one example use of lead 1700, a system can include baroreceptor stimulation circuitry and sensor circuitry. The circuitry can be within pulse generator 1140 (Figure 8) or be a separate system communicating wirelessly with the pulse generator. One or more leads can be connected to the sensor circuitry and baroreceptor stimulation circuitry. The baroreceptor stimulation circuitry is used to apply electrical stimulation pulses to desired baroreceptors sites, such as baroreceptor sites in the pulmonary artery, through one or more stimulation electrodes, such as electrode 1130 on biased portion 1722. The sensor circuitry is used to detect and process ANS nerve activity and/or surrogate parameters such as blood pressure, respiration and the like, to determine the ANS activity.

Lead 1700, for example, is capable of being intravascularly introduced to stimulate a baroreceptor site, such as the baroreceptor sites in the pulmonary artery, aortic arch, or ligamentum arteriosum. One or more additional electrodes can be provided to pace and/or sense cardiac activity, such as that which may occur within the right ventricle with the sensor 1710 located in or near the pulmonary artery and programmed to stimulate and sense, either directly or indirectly through surrogate parameters, baroreflex activity.

Figure 14 shows a lead 1800 according to one embodiment, lead 1800 includes a distal portion 1820 including a biased circular portion 1822. In this embodiment, a plurality of discrete electrodes 1824 are placed around the outer circumference of the circular portion 1822. In other embodiments, the entire biased circular portion can be an exposed electrode. Circular biased portion 1822 is dimensioned to fixate the distal end 1820 within the pulmonary artery. For example, the biased circular portion can have an outer diameter of between 10 mm and 20 mm. In one embodiment, the circular plane of the distal portion 1820 of the lead 1800 is perpendicular to the long axis 1830 of the lead body (i.e. shaped like a lasso). A distal end fashioned in this way tends to stimulate the pulmonary artery in

a plane or cross section of the artery. Other embodiments can use other angles as needed.

To provide hypertension therapy according to one or more embodiments, a lead, such any lead discussed herein, is intravascularly inserted through a peripheral  
5 vein and through the tricuspid valve into the right ventricle of the heart and then from the right ventricle through the pulmonary valve into the pulmonary artery. An electrode on the lead is fixated to a region of the pulmonary artery having one or more baroreceptors. One example passively fixates the electrode proximate the ligamentum arteriosum of the left pulmonary artery. In one embodiment, the pulse  
10 generator is designed to intermittently pace the baroreceptor with a low-voltage, high frequency pulse train. For example, the baroreceptor can be paced for about 5 to 10 seconds each minute at a voltage of about 0.1 volts to 10 volts and a frequency between about 10 Hz and 150 Hz. Some examples utilize a voltage between about 1 volt to about 10 volts. One embodiment delivers at least a 10 hertz pulse train via  
15 the electrode. In some embodiments, the pulse generator can deliver a waveform of 30 hertz, 2.5 msec, at 5 volts. Some embodiments deliver a waveform of 100 hertz, 1.0 msec, at 1, 3, or 5 volts, for example.

The leads of the present subject matter are easy to implant and deliver uncomplicated waveforms. Moreover, the baroreceptor pacing response is  
20 immediate and reversible.

As noted, further embodiments can include a sensor to monitor blood pressure. The sensor can sense a physiological parameter regarding an efficacy of the baroreflex therapy and provides a signal indicative of the efficacy of the baroreflex therapy. For example, a controller can be connected to a pulse generator  
25 to control the baroreflex stimulation signal and to the sensor to receive the signal indicative of the efficacy of the baroreflex therapy. In some examples, the pulse generator can be further adapted to generate a cardiac pacing signal, and the lead can include a second electrode to be positioned to deliver the cardiac pacing signal to



capture the heart. Embodiments of the present electrodes allows for chronically indwelling, is easy to implant, and is safe and reliable.

In various embodiments of baroreceptor pacing according to the present subject matter, the system can deliver the pulse train intermittently with no sensing, or the system can be activated by the user when the user is at rest, or it can be activated by a timer to be periodically turned off and on, or it can be activated when the user goes to sleep, for example.

According to various embodiments, the stimulator circuitry and sensing circuitry of the present system can include one or more functions as described in the commonly assigned U.S. patent application filed on the same date as the present application and incorporated by reference in its entirety: "Baroreflex Stimulation System to Reduce Hypertension," Ser. No. 10/746,134, filed on Dec 24, 2003 (Attorney Docket No. 279.675US1).

For example, various embodiments of the present subject matter relate to baroreflex stimulator systems. Such baroreflex stimulation systems are also referred to herein as neural stimulator (NS) devices or components. Examples of neural stimulators include anti-hypertension (AHT) devices or AHT components that are used to treat hypertension. Various embodiments of the present subject matter include stand-alone implantable baroreceptor stimulator systems, include implantable devices that have integrated NS and cardiac rhythm management (CRM) components, and include systems with at least one implantable NS device and an implantable CRM device capable of communicating with each other either wirelessly or through a wire lead connecting the implantable devices. Integrating NS and CRM functions that are either performed in the same or separate devices improves aspects of the NS therapy and cardiac therapy by allowing these therapies to work together intelligently.

Thus, various embodiments of the present subject matter provide an implantable NS device that automatically modulates baroreceptor stimulation using

an IPS. Integrating the pressure sensor into the lead provides localized feedback for the stimulation. This localized sensing improves feedback control. For example, the integrated sensor can be used to compensate for inertia of the baroreflex such that the target is not continuously overshoot. According to various embodiments, the device monitors pressure parameters such as mean arterial pressure, systolic pressure, diastolic pressure and the like. As mean arterial pressure increases or remains above a programmable target pressure, for example, the device stimulates baroreceptors at an increased rate to reduce blood pressure and control hypertension.

As mean arterial pressure decreases towards the target pressure, the device responds by reducing baroreceptor stimulation. In various embodiments, the algorithm takes into account the current metabolic state (cardiac demand) and adjusts neural stimulation accordingly. A NS device having an IPS is able to automatically modulate baroreceptor stimulation, which allows an implantable NS device to determine the level of hypertension in the patient and respond by delivering the appropriate level of therapy. However, it is noted that other sensors, including sensors that do not reside in an NS or neural stimulator device, can be used to provide close loop feedback control.

An aspect of the present subject matter relates to a chronically-implanted stimulation system specially designed to treat hypertension by monitoring blood pressure and stimulating baroreceptors to activate the baroreceptor reflex and inhibit sympathetic discharge from the vasomotor center. Baroreceptors are located in various anatomical locations such as the carotid sinus and the aortic arch. Other baroreceptor locations include the pulmonary artery, including the ligamentum arteriosum, and sites in the atrial and ventricular chambers. In various embodiments, the system is integrated into a pacemaker/defibrillator or other electrical stimulator system. Components of the system include a high-frequency pulse generator, sensors to monitor blood pressure or other pertinent physiological parameters, leads to apply electrical stimulation to baroreceptors, algorithms to

determine the appropriate time to administer stimulation, and algorithms to manipulate data for display and patient management.

Various embodiments relate to a system that seeks to deliver electrically mediated NS therapy, such as AHT therapy, to patients. Various embodiments combine a “stand-alone” pulse generator with a minimally invasive, unipolar lead that directly stimulates baroreceptors in the vicinity of the heart, such as in the pulmonary artery. This embodiment is such that general medical practitioners lacking the skills of specialist can implant it. Various embodiments incorporate a simple implanted system that can sense parameters indicative of blood pressure. This system adjusts the therapeutic output (waveform amplitude, frequency, etc.) so as to maintain a desired quality of life. In various embodiments, an implanted system includes a pulse generating device and lead system, the stimulating electrode of which is positioned near endocardial baroreceptor tissues using transvenous implant technique(s).

Another embodiment includes a system that combines NS therapy with traditional bradyarrhythmia, tachyarrhythmia, and/or congestive heart failure (CHF) therapies. Some embodiments use an additional “baroreceptor lead” that emerges from the device header and is paced from a modified traditional pulse generating system. In another embodiment, a traditional CRM lead is modified to incorporate proximal electrodes that are naturally positioned near baroreceptor sites. With these leads, distal electrodes provide CRM therapy and proximal electrodes stimulate baroreceptors.

For example, Figure 15 schematically shows an unbiased lead 1900 having an electrode 1910 on a distal end and an active or positive fixation mechanism, such as a helix 1920. Electrode 1910 is intended to be implanted at or near a site of high baroreceptor concentration, such as baroreceptor site 206B in the pulmonary artery 204. At implant, lead 1900 would be passed through the heart and into the pulmonary artery. With the distal end of lead 1900 generally straight (unbiased), the

act of implantation would naturally position the distal electrode end 1910 at or near baroreceptor site 206B. Stimulation at the 206B location by a single electrode can be preferable, in some instances, to advancing a longer lead device deeper into the pulmonary artery to attempt stimulation of a number of diffuse locations.

5           Various embodiments of the present subject matter relate to a method of sensing atrial activation and confining pulmonary artery stimulation to the atrial refractory period, preventing unintentional stimulation of nearby atrial tissue. An implantable baroreceptor stimulation device monitors atrial activation with an atrial sensing lead. A lead in the pulmonary artery stimulates baroreceptors in the vessel  
10 wall. However, instead of stimulating these baroreceptors continuously, the stimulation of baroreceptors in the pulmonary artery occurs during the atrial refractory period to avoid capturing nearby atrial myocardium, maintaining the intrinsic atrial rate and activation. Various embodiments of the present subject matter combine an implantable device for stimulating baroreceptors in the wall of  
15 the pulmonary artery with the capability for atrial sensing. Various embodiments stimulate baroreceptors in the cardiac fat pads, in the heart chambers, and/or afferent nerves.

          In some embodiments, the pulse generator can include a transceiver and associated circuitry for use to communicate with a programmer or another external  
20 or internal device. Various embodiments have wireless communication capabilities. For example, some transceiver embodiments use a telemetry coil to wirelessly communicate with a programmer or another external or internal device.

          The above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing  
25 the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

What is claimed is:

1. An apparatus comprising:  
a flexible lead body extending from a proximal end to a distal end;  
5 an electrode coupled to the lead body;  
an implantable pulse generator electrically coupled to the electrode, the  
implantable pulse generator being adapted to deliver a baroreflex stimulation signal  
to a baroreceptor in the pulmonary artery via the electrode;  
means for passively fixating the electrode within the pulmonary artery.  
10
2. The apparatus of claim 1, wherein the means for passively fixating includes  
an expandable stent structure coupled to the lead.
3. The apparatus of claim 2, wherein the stent structure includes an expanded  
15 diameter dimensioned to abut a wall of a pulmonary artery.
4. The apparatus of claim 3, wherein the expanded diameter is about 10 to 20  
mm.
- 20 5. The apparatus of claim 2, wherein the expandable stent expands to fix the  
lead in place by frictional forces.
6. The apparatus of claim 2, wherein the expandable stent structure includes a  
length of at least about 1 cm.  
25
7. The apparatus of claim 1, wherein the means for passively fixating includes a  
biased portion proximate the distal end of the lead, the biased portion having an  
outer diameter dimensioned to abut a wall of a pulmonary artery.

8. An apparatus comprising:  
a flexible lead body extending from a proximal end to a distal end;  
an expandable electrode coupled proximate the distal end, the expandable  
5 electrode having an expanded diameter dimensioned to abut a wall of a pulmonary  
artery; and  
an implantable pulse generator electrically coupled to the expandable  
electrode, wherein the implantable pulse generator is adapted to deliver a baroreflex  
stimulation signal to a baroreceptor in the pulmonary artery via the electrode.
- 10 9. The apparatus of claim 8, wherein the expandable electrode includes a mesh  
surface.
10. The apparatus of claim 8, wherein the expandable electrode expands to fix  
15 the lead in place by frictional forces.
11. The apparatus of claim 8, wherein the expandable electrode includes a length  
of at least about 1 cm.
- 20 12. The apparatus of claim 8, wherein the expandable electrode includes an  
expanded diameter of about 10 to 20 mm.
13. The apparatus of claim 8, wherein the expandable electrode includes at least  
a partially electrically insulated surface.
- 25 14. The apparatus of claim 8, wherein the lead includes a second electrode  
located proximally from the expandable electrode.

15. The apparatus of claim 8, wherein the lead further includes a sensor to monitor blood pressure.

16. The apparatus of claim 8, wherein the electrode is adapted to be located near  
5 the ligamentum arteriosum of the left pulmonary artery.

17. The apparatus of claim 8, further including a sensor to sense a physiological parameter regarding an efficacy of the baroreflex therapy and to provide a signal indicative of the efficacy of the baroreflex therapy.

10

18. The apparatus of claim 17, further including a controller connected to the pulse generator to control the baroreflex stimulation signal and to the sensor to receive the signal indicative of the efficacy of the baroreflex therapy.

15 19. An apparatus comprising:

a flexible lead body extending from a proximal end to a distal end, the distal end having a biased portion having an outer diameter dimensioned to abut a wall of a pulmonary artery;

an electrode coupled proximate the distal end; and

20 an implantable pulse generator electrically coupled to the electrode, wherein the implantable pulse generator is adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.

20. The apparatus of claim 19, wherein the biased portion has an outer diameter  
25 between about 10 mm and about 20 mm.

21. The apparatus of claim 19, wherein the biased portion is adapted to fix the lead in place by frictional forces.

22. The apparatus of claim 19, wherein the biased portion includes a spiral configuration.
- 5 23. The apparatus of claim 19, wherein the electrode includes a porous surface.
24. The apparatus of claim 19, wherein the lead includes two or more discrete electrodes located on the biased portion of the lead.
- 10 25. The apparatus of claim 19, wherein the lead includes a second electrode located proximally from the distal end.
26. The apparatus of claim 19, further including a sensor to sense a physiological parameter regarding an efficacy of the baroreflex therapy and to provide a signal  
15 indicative of the efficacy of the baroreflex therapy.
27. The apparatus of claim 26, further including a controller connected to the pulse generator to control the baroreflex stimulation signal and to the sensor to receive the signal indicative of the efficacy of the baroreflex therapy.  
20
28. The apparatus of claim 19, wherein the biased portion of the distal end is adapted to passively fixate the electrode within the pulmonary artery.
29. The apparatus of claim 19, wherein the biased portion includes a circular  
25 structure.
30. An apparatus comprising:  
an electrode adapted to be fixated within a pulmonary artery; and



means for delivering a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.

31. The apparatus of claim 30, wherein the electrode is adapted to be passively  
5 fixated within the pulmonary artery.

32. The apparatus of claim 30, wherein the electrode is adapted to be actively  
fixated within the pulmonary artery.

1/6




FIG. 1




FIG. 2

2/6




FIG. 3




FIG. 4




FIG. 5

SUBSTITUTE SHEET (RULE 26)

3/6




FIG. 6




FIG. 7




FIG. 8

4/6




FIG. 9




FIG. 10

5/6




FIG. 11




FIG. 12




FIG. 13

6/6




FIG. 14




FIG. 15

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61N1/36 A61N1/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/120304 A1 (MEST ROBERT A) 29 August 2002 (2002-08-29) abstract; figures 4-7 claims 1,6	30-32
A	US 6 522 926 B1 (KIEVAL ROBERT S ET AL) 18 February 2003 (2003-02-18) the whole document	1-32
A	WO 03/082080 A (CVRX, INC) 9 October 2003 (2003-10-09) the whole document	1-32
A	US 6 178 349 B1 (KIEVAL ROBERT S) 23 January 2001 (2001-01-23) the whole document	1-32

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

11 March 2005

Date of mailing of the international search report

22/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Wetzig, T



Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002120304	A1	29-08-2002	NONE	
US 6522926	B1	18-02-2003	AU 9479901 A	08-04-2002
			EP 1330288 A1	30-07-2003
			JP 2004526471 T	02-09-2004
			WO 0226314 A1	04-04-2002
			US 2004019364 A1	29-01-2004
			US 2004254616 A1	16-12-2004
WO 03082080	A	09-10-2003	AU 2003220574 A1	13-10-2003
			AU 2003220599 A1	13-10-2003
			EP 1487535 A2	22-12-2004
			EP 1487536 A2	22-12-2004
			WO 03082080 A2	09-10-2003
			WO 03082403 A2	09-10-2003
			US 2004019364 A1	29-01-2004
			US 2004010303 A1	15-01-2004
US 6178349	B1	23-01-2001	NONE	